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Magnesium deﬁciency in pregnancy frequently occurs because of inadequate or low intake of magnesium. Magnesium deﬁciency
during pregnancy can induce not only maternal and fetal nutritional problems, but also consequences that might last in oﬀspring
throughout life. Many epidemiological studies have disclosed that small for gestational age (SGA) is associated with an increased
risk of insulin resistance in adult life. We reported that intracellular magnesium of cord blood platelets is lower in SGA groups
than that in appropriate for gestational age groups, suggesting that intrauterine magnesium deﬁciency may result in SGA. Taken
together, intrauterine magnesium deﬁciency in the fetus may lead to or at least program insulin resistance after birth. In this
review, we propose that intrauterine magnesium deﬁciency may induce metabolic syndrome in later life. We discuss the potential
contribution of aberrant magnesium regulation to SGA and to the pathogenesis of metabolic syndrome.
1.Introduction
Magnesium (Mg) is an important cofactor for the enzymes
that are involved in carbohydrate metabolism: an important
role of Mg in insulin action has been reported [1, 2]; low
serum and intracellular Mg ([Mg2+]i) concentrations are
associated with insulin resistance, impaired glucose toler-
ance, and decreased insulin secretion [3, 4]. Furthermore,
lower dietary Mg intake could cause insulin resistance both
in children and adults [5, 6]. Based on these ﬁndings, we
studied whether low [Mg2+]i in the fetus would be one of the
critical abnormalities associated with small for gestational
age (SGA).
In addition, several studies have shown the association
of size at birth or indices in poor fetal growth with later
development of metabolic syndrome and insulin resistance
[7].Halesetal.proposedthatimpairedglucosetoleranceand
type 2 diabetes might arise as a result of programming [8].
Programming is a term used to describe persistent changes
in organ structure and function caused by exposure to
adverse environmental inﬂuences during critical periods of
development [9]. These ﬁndings have led to the “fetal origin”
hypothesis, which proposes that fetal adaptation to an
adverse intrauterine environment aﬀecting fetal growth may
program life-long physiological changes [10]. It has been
proposed that various fetal growth patterns and intrauterine
growth retardation (IUGR) arise as a result of an early
stimulus or insult. Since both fetal weight and length gains
are closely related, there is much overlap between SGA and
IUGR. We focus on intrauterine undernutrition and SGA.
SGA is deﬁned as birth weight and/or length at least 2
standard deviations below the mean for gestational age.
In this review, we discuss the potential contribution of
aberrant Mg regulation to SGA and to the pathogenesis of
metabolic syndrome later in life.
2. Magnesium Deﬁciency DuringPregnancy
It is reported that the amount of maternal Mg intake is not
only associated with pregnancy outcome but also with infant
outcome [11]. The mean daily intake of Mg (284.3mg/day)2 Journal of Pregnancy
during pregnancy was found to be lower than recommended
[12]. For example, Mg deﬁciency is reported to occur in
44% of pregnant Indian women [13]. Another study has
demonstrated that mothers who drink water containing high
amounts of Mg have a reduced risk of having very low
birth weight infants (less than 1,500g of birth weight) [14].
By the end of a normal pregnancy, the fetus is believed
to have acquired approximately 28g of calcium, 16g of
phosphorous, and 0.7g of Mg, mostly during the third
trimester, also the time when 80% of fetal accretion of Mg
occurs [15].
The fetal circulation contains higher levels of total
calcium, ionized calcium, and Mg compared to maternal
blood [16]. In the placental membrane, copper and selenium
share the same transport pathway along a concentration
gradient in the maternal-fetal direction, while Mg and iron
use predominantly an active transport pathway [17]. In fact,
evidence for an active transport mechanism for Mg in the
placenta has been demonstrated in cultured trophoblast cells
in which low [Mg2+]i is maintained by the function of a
Na+/Mg2+ exchanger [18]. Mg levels in umbilical cord blood
are the lowest in preterm low birth weight babies, followed
by term low birth weight babies and are the highest in term
controls (P<. 05) [19].
Calcium and Mg have an immediate eﬀect on placental
vascular ﬂow. Reduced placental vascular ﬂow is at least, in
part, responsible for placental insuﬃciency and fetal growth
retardation(FGR).CalciumandMgarecofactorsofavariety
of enzymes. A variety of hormones, cytokines, and growth
factors produced by fetal membranes and the placenta can
actlocallyonthemyometrium[20].Theabilityoftheuterine
artery to dilate during pregnancy may be speciﬁcally related
to the upregulation of multiple pathways for the production
of nitric oxide [21]. The activity of constitutive nitric oxide
synthase is dependent on calcium and is inhibited by a
reduction in the concentration of Mg [22].
Blood Mg levels were reportedly lower in women with
severe pre-eclampsia than in healthy pregnant women
(1.63±0.05mg/dL versus 1.87±0.05mg/dL; P<. 001)
[23]. Mg is widely used in obstetric practice to treat pre-
eclampsia. Therapeutic levels of Mg have also been found to
p r o d u c es p e c i ﬁ cp l a c e n t a le ﬀects such as vasodilation [24].
From an in vitro study of human umbilical artery resistance
[25], Mg sulfate was found to exert a relaxant eﬀect on
umbilical arterial tone attenuating the vasoconstrictor eﬀect
of angiotensin II and endothelin-1 in the fetal-placental vas-
culature. Mg sulfate used for the treatment of pre-eclampsia
or hypertensive disease in pregnancy may have beneﬁcial
eﬀects on the fetoplacental circulation. Prenatal treatment
with Mg sulfate may inﬂuence calcium homeostasis and
nonenzymatic antioxidant reserve in erythrocytes of preterm
newborns [26].
3. Mg Supplements andPregnancy Outcome
It is well known that plasma Mg falls in pregnancy because of
accumulationofionintheplacentaandfetus.Mgistherefore
widely given as a supplement during pregnancy, particularly
in cases of preterm labor. There are several reports that oral
Mg supplementation in pregnancy is safe and that it has a
positive eﬀect on fetal morbidity [27]. Patients in preterm
labor have signiﬁcantly depressed serum Mg levels, while in
patients with pre-eclampsia, Mg levels are not signiﬁcantly
diﬀerent from that of the controls [28]. Mg supplementation
was found to decrease the rate of FGR, premature rupture
of membranes, and premature delivery in risk pregnancies
treated with betamimetics [29]. Oral Mg supplementation
given before the 25th week of gestation is associated with
a lower frequency of preterm births, a lower frequency of
low birth weight, and fewer SGA infants compared with the
placebo [30]. Mg intake in 513 women who were near the
end of their ﬁrst trimester of pregnancy was determined
from records of food consumption. Mg intake correlated
with weight, length, and head circumference at birth as well
as length of gestation up to a threshold of around 3,200g
of birth weight [31]. On the other hand, Mg supplements
(100mg/day) taken during the second and third trimesters
had no eﬀect on the outcome of the pregnancy. The eﬀect
of Mg compared with placebo in a randomized double-
blind controlled study of patients with pregnancy-induced
hypertension was investigated [32].Mgsupplementationwas
found to be beneﬁcial in the management of pregnancy-
induced hypertension.
At present, there is insuﬃcient high-quality evidence to
show that dietary Mg supplementation during pregnancy is
beneﬁcial [30]. Any inﬂuence of Mg has been conﬁned to
the ﬁrst trimester or earlier. It is important to determine the
timing and dose of Mg supplementation as both factors may
alter the pregnancy outcome.
4.The Relationof SGAtoIntracellular
MagnesiuminCordBloodPlatelets
We have previously reported that intracellular magnesium
([Mg2+]i) is lower in children with diabetes mellitus and in
children who are obese [33]. In the type 2 diabetes mellitus
and obese groups, platelets responded well to insulin. Under
insulin-resistant states, [Mg2+]i decreases before the poor
reactivity to insulin occurs in platelets. From these ﬁndings,
we hypothesize that [Mg2+]i is decreased earlier than when
poor reactivity to insulin develops in platelets exposed to
an insulin resistant environment. This suggests that low
[Mg2+]i may be an intrinsic abnormality in infants with
low birth weight [33]. To test this hypothesis, we studied
the relationship of [Mg2+]i in cord blood platelets to birth
weight [34]. We found that mean basal [Mg2+]i,b u tn o t
plasma magnesium, is lower in SGA than in the appropriate
for gestational age (AGA) groups (323±162µmol/L versus
488±132µmol/L, P = .004 ). Basal [Mg2+]i signiﬁcantly
correlates with birth weight (P<. 0001) as well as cord
plasma leptin (P = .031) and IGF-1 (P<. 001) [35].
[Mg2+]i as well as leptin and IGF-1 reﬂects the extent of
fetal growth. Also, [Mg2+]i signiﬁcantly correlates with the
quantitative insulin sensitivity check index (QUICKI)) (P<
.001). Decreased [Mg2+]i in SGA might underlie the initial
pathophysiological events that lead to insulin resistance.Journal of Pregnancy 3
S e v e r a lf a c t o r sa r er e p o r t e dt oa ﬀect [Mg2+]i.F o re x a m -
ple,hyperglycemiamayhaveaneﬀectonMg2+ transportand
induce a decline of [Mg2+]i. Barbagallo et al. reported that
responses to hyperglycemia in vitro were blunted in adult
hypertensive subjects and that these responses were closely
linked to basal [Mg2+]i levels [36]. In our study, we found no
correlation between cord plasma glucose and basal [Mg2+]i
levels. In addition, we did not ﬁnd any signiﬁcant diﬀerence
in plasma glucose levels between the SGA and AGA groups.
Intrauterine glucose levels may have less of an eﬀect on
inducing SGA or low [Mg2+]i.A s[ M g 2+]i plays a promotive
role in fetal growth, low [Mg2+]i m a yp a r t l yb er e s p o n s i b l e
for SGA.
As low [Mg2+]i is an intrinsic abnormality seen in
infants with low birth weight, it is considered that fetal Mg
deﬁciency is an important determinant of insulin resistance
in later life [33]. In fact, our data was supported by a recent
animal study demonstrating that maternal Mg restriction
irreversibly increases body fat and induces insulin resistance
in pups by 6months of age [37].
5.Fetal Programming
The fetal origin hypothesis by Barker et al. [8–10] states
that fetal undernutrition in middle to late gestation leads to
disproportionate fetal growth programs and later metabolic
diseases. Fetal programming is a phenomenon in which
alterations in fetal growth and development in response
to the prenatal environment have long-term or perma-
nent eﬀects. This theory was further established in the
category of developmental origins of health and disease
(DOHaD) [38]. The mechanisms thought to be responsible
for fetal programming include the direct eﬀects on cell
number, altered stem cell function, and the resetting of
regulatory hormonal axes: hypothalamic-pituitary-adrenal
axis [39, 40] and growth hormone insulin-like growth
factor axis [41]. One of the underlying mechanisms for
the postulated early-life programming is that of epigenet-
ics. Altered epigenetic regulation of genes in phenotype
induction could possibly give rise to interventions that
modify long-term disease risk associated with unbalanced
nutrition in early life [42]. Venu et al. reported that fasting
insulin and Homeostasis Model Assessment-Insulin Resis-
tance (HOMA-IR) increased in oﬀspring from Mg-restricted
dams at 6months of age [37]. Maternal and postnatal
Mg status is important in the long-term programming
of body adiposity and insulin secretion in rat oﬀspring
[43].
Although low birth weight and poor prenatal nutrition
are strongly associated with metabolic syndrome in later
life, postnatal catch-up growth was recently considered to
also be a pivotal element associated with the development
of various pathological conditions [44]. The concept of a
sensitive or crucial period that operates to cause long-term
changes in development and adverse outcomes later in life is
an intriguing one and should be the focus of more studies in
the future.
6. Conclusion
Birth weight is only a crude index of early growth and
indicates nothing about the success of a fetus in achieving its
growth potential. [Mg2+]i may be a marker of early growth
restriction, which may be of future diagnostic use as an
early predictor of adult diseases. Low [Mg2+]i, which may
represent the prenatal programming of insulin resistance,
has lifelong eﬀects on metabolic regulation. A biological
interpretation of the association between birth size and risk
of insulin-resistant diseases should emphasize the possible
underlying roles of [Mg2+]i.
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